Literature DB >> 3625987

Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Göteborg, Sweden.

O Samuelsson, L Wilhelmsen, O K Andersson, K Pennert, G Berglund.   

Abstract

The relationship of cardiovascular disease (CVD) to the control of blood pressure (BP) and serum cholesterol levels was studied in 686 treated, middle-aged hypertensive men whose condition was followed up for 12 years. Both mean in-study BP (P less than .001) and serum cholesterol levels (P less than .001) were better predictors for CVD than the respective entry levels (both not significant) in multivariate analysis. Surprisingly, for mean in-study systolic and diastolic BP there seemed to be a level (approximately 150 and 85 mm Hg, respectively) below which further reduction of BP had no additional benefit from treatment. Analyses of CVD morbidity in relationship to changes in BP and serum cholesterol levels clearly showed that a combined reduction of both risk factors was necessary to achieve a substantial reduction in morbidity. These study findings indicate that (1) it may be unfavorable to reduce BP below a certain level in middle-aged hypertensive men; and (2) other risk factor interventions must be improved to improve the patient's prognosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3625987

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  31 in total

1.  Preventive medicine in primary care: management of hyperlipidaemia.

Authors:  B Lewis
Journal:  Br J Gen Pract       Date:  1992-02       Impact factor: 5.386

Review 2.  Hypertension.

Authors:  G W Ching; D G Beevers
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

Review 3.  Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?

Authors:  G J Magarian
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

4.  The J-curve interpreted. An alternative explanation of the results.

Authors:  M A Sekeres; J T Farrar; B L Strom
Journal:  J Gen Intern Med       Date:  1996-06       Impact factor: 5.128

5.  Diastolic blood pressure and the risk of primary cardiac arrest among pharmacologically treated hypertensive patients.

Authors:  D S Siscovick; T E Raghunathan; B M Psaty; T D Koepsell; L Cobb; P M Rautaharju; E H Wagner
Journal:  J Gen Intern Med       Date:  1996-06       Impact factor: 5.128

6.  Blood pressure control and mortality--is there a J-shaped curve?

Authors:  H Wedel
Journal:  Drugs       Date:  1989       Impact factor: 9.546

Review 7.  Experiences from hypertension trials--effects on stroke and coronary heart disease.

Authors:  G Berglund
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 8.  Combined antihypertensive and lipid-lowering treatment.

Authors:  Maurizio Cesari; Achille C Pessina
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

Review 9.  The J-curve in hypertension.

Authors:  John Cruickshank
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

10.  Hyperinsulinemia in hypertension: increased secretion, reduced clearance or both?

Authors:  D Giugliano; A Quatraro; A Minei; N De Rosa; L Coppola; F D'Onofrio
Journal:  J Endocrinol Invest       Date:  1993-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.